A new sequencing-based method developed by Duke University's Kate Meyer is one of several that can detect RNA methylation without the use of antibodies.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
The partners will codevelop software for both small and large variant detection and Illumina will create hardware-accelerated versions for its Dragen platform.
